This, in concert with anti-PD-1 ICB, significantly increases tumor infiltration by lymphocytes likely through CXCL9 engagement with its cognate receptor expressed by these cells-CXC motif chemokine receptor 3 (CXCR3). Here, CXCL9 is linked to neoplasm.